Skip to main content

Table 1 Characteristics of the patients participating in the Clinical Study

From: A phase I clinical study of vaccination of melanoma patients with dendritic cells loaded with allogeneic apoptotic/necrotic melanoma cells. Analysis of toxicity and immune response to the vaccine and of IL-10 -1082 promoter genotype as predictor of disease progression

Pt # Sex Age Stage Mts Site MN Cells obtained (×109cells) Dose of DC/Apo-Nec (×106cells) No. Vacc Clin. Evolution (12/1/07) IL-10 Promoter Genotype
1 F 42 III LN 3.5 5 4 P (10 m) AA
2 F 57 III ND 3.6 5 4 NED (62 m+) AG
3 M 32 III ND 3.3 5 4 NED (43 m+) AA
4 F 17 III ND 4.4 5 4 NED (53 m+) AG
5 M 56 IV L,SC 5 10 4 P (4 m) AA
6 M 60 III ND 1.5 3 4 NED (45 m+) AA
7 M 27 IV SC 4.2 10 2 WP (1 m) AA
8 M 26 IV ND 3.6 10 4 P (7 m) AA
9 F 42 III ND 7.5 15 4 NED (79m+) AG
10 M 34 IV LN 6.2 15 4 P (11 m) AG
11 M 44 IV L 4.7 15 4 P (4 m) AG
12 M 56 III ND 8 15 4 NED (33m+) AG
13 M 47 IIC ND 9.3 20 4 NED (34 m+) AA
14 M 30 III ND 7.5 20 4 NED (47 m+) GG
15 M 52 IV LN 6 20 4 P (10 m) AA
16 F 57 IV SC 8.2 20 4 P(6 m) AA
  1. ND: non-detectable disease after surgery; SC: subcutaneous; L: Lung; LN: Lymph node; NED: non-evident disease; P: progression; D: deceased. WP: withdrawn from protocol. m: months of follow-up from last surgery.